Keith Gottesdiener, M.D.

“In addition, effective as of September 26, 2025, Dr. Gottesdiener was appointed to serve as a member of the Compensation Committee of the Board (the "Compensation Committee") and as a member and Chair of the Research and Development Committee of the Board (the "R&D Committee").”

“On September 25, 2025 (the "Appointment Date"), the Board of Directors (the "Board") of Septerna, Inc. (the "Company") expanded the size of the Board from seven to eight directors and appointed Keith Gottesdiener, M.D. to serve as a member of the Board and as a Class I director, to hold office for a three-year term expiring at the Company's annual meeting of stockholders to be held in 2028 and until his successor is duly elected and qualified, or until his earlier death, resignation or removal, in each case effective as of the Appointment Date.”